Journal: Cells
Article Title: Synovium-Derived and Bone-Derived Mesenchymal Stem/Stromal Cells from Early OA Patients Show Comparable In Vitro Properties to Those of Non-OA Patients
doi: 10.3390/cells13151238
Figure Lengend Snippet: Immunophenotype of the in vitro expanded primary cells at passage 3. ( a ) The percentage of the cells expressing the positive markers CD73, CD90 and CD105 (upper row), and negative markers CD45/CD19/CD14 (lower row). Red dash lines represents the recommendation of the International Society for Cellular Therapy criteria suggesting that positive markers are expressed by more than 95% of all of the cells and negative markers are expressed by less than 2% of all of the cells. No differences for synovium and bone-derived cells between both groups of patients (general linear model with Bonferroni post hoc) were found. Individual samples and means are shown. S1 + S2 + S3 presents a group of combined data from S1, paralabral synovium, S2, cotyloid fossa and S3, peripheral inner surface of the joint capsule. ( b ) Shown are representative dot plots for each tissue type independent of patient group. S1, paralabral synovium, S2, cotyloid fossa, S3, peripheral inner surface of the joint capsule.
Article Snippet: Briefly, the following antibodies were used: anti-CD105 MEM-226 FITC (ThermoFisher Scientific), anti-CD90 DG3 FITC, anti-CD73 AD2 APC (Miltenyi Biotec) and viability dye eFluor 780 (ThermoFisher Scientific).
Techniques: In Vitro, Expressing, Derivative Assay
